Compare Figs Inc (FIGS) vs Johnson & Johnson (JNJ) Price & Performance

FIGS trades at $14.41, up 0.14% with strong technical momentum as moving averages signal bullish sentiment. The company reported impressive Q2 2026 results with 29% revenue growth and raised full-year guidance, while maintaining robust gross margins of 68.9%. Recent institutional buying and positive analyst coverage support the stock's upward trajectory despite rich valuation multiples.

Outlook remains positive with accelerating revenue growth and margin expansion, though the premium valuation (P/E 43.2) creates high expectations. Key risks include execution challenges in the second half and competitive pressures in healthcare apparel. The consensus price target of $19.50 suggests 35% upside potential from current levels.

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.